Correlation between improvement in visual acuity and QOL after Ranibizumab treatment for age-related macular degeneration patients: QUATRO study

Abstract Background To evaluate the correlation between visual acuity improvement and vision-related QOL after ranibizumab treatment in Japanese patients with AMD. Methods In this one-year prospective, interventional, open-label, multicenter study involving four sites, neovascular AMD were enrolled observed for 12 months. Treatment-naïve received 0.5 mg as needed three initial monthly doses. The best corrected (BCVA) central macular thickness (CMT) measured at every visit. Evaluations 25-item National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) patient satisfaction questionnaire performed baseline 3 months treatment. primary endpoint was change BCVA outcomes also assessed better poor BVCA subgroups. Results 100 patients. mean logMAR improved significantly from 0.43 to 0.30 ( p < 0.0001), 0.28 0.0001). NEI-VFQ-25 composite scores 79.48 84.13 86.0 12-month changes score showed significant correlation. group (decimal ≤0.5), there a =0.02) but not > 0.6, =0.1) There no differences =0.54) =0.23). average CMT 340 264 μm 0.0001) 268 (p< Conclusions Intravitreal resulted acuity, anatomical change, function Significant seen function, correlated VA, except immediately loading dose higher VA. patients’ remained unchanged during period. Trial registration This is registered UMIN Clinical Trials Registry UMIN000012013 ). Registered October 10, 2013, prospective study.